FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783295481> ?p ?o ?g. }

• W2783295481 abstract "An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary immune checkpoint blockade (ICB) is unknown. We investigated the utility of NLR in metastatic renal cell carcinoma (mRCC) patients treated with PD-1/PD-L1 ICB.We examined NLR at baseline and 6 (±2) weeks later in 142 patients treated between 2009 and 2017 at Dana-Farber Cancer Institute (Boston, USA). Landmark analysis at 6 weeks was conducted to explore the prognostic value of relative NLR change on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Cox and logistic regression models allowed for adjustment of line of therapy, number of IMDC risk factors, histology and baseline NLR.Median follow up was 16.6 months (range: 0.7-67.8). Median duration on therapy was 5.1 months (<1-61.4). IMDC risk groups were: 18% favorable, 60% intermediate, 23% poor-risk. Forty-four percent were on first-line ICB and 56% on 2nd line or more. Median NLR was 3.9 (1.3-42.4) at baseline and 4.1 (1.1-96.4) at week 6. Patients with a higher baseline NLR showed a trend toward lower ORR, shorter PFS, and shorter OS. Higher NLR at 6 weeks was a significantly stronger predictor of all three outcomes than baseline NLR. Relative NLR change by ≥25% from baseline to 6 weeks after ICB therapy was associated with reduced ORR and an independent prognostic factor for PFS (p < 0.001) and OS (p = 0.004), whereas a decrease in NLR by ≥25% was associated with improved outcomes.Early decline and NLR at 6 weeks are associated with significantly improved outcomes in mRCC patients treated with ICB. The prognostic value of the readily-available NLR warrants larger, prospective validation." @default.
• W2783295481 created "2018-01-26" @default.
• W2783295481 creator A5000204340 @default.
• W2783295481 creator A5005321013 @default.
• W2783295481 creator A5023841393 @default.
• W2783295481 creator A5034541004 @default.
• W2783295481 creator A5039044023 @default.
• W2783295481 creator A5042777250 @default.
• W2783295481 creator A5045221892 @default.
• W2783295481 creator A5049425681 @default.
• W2783295481 creator A5052504518 @default.
• W2783295481 creator A5053962411 @default.
• W2783295481 creator A5055738663 @default.
• W2783295481 creator A5061593455 @default.
• W2783295481 creator A5066816851 @default.
• W2783295481 creator A5074756323 @default.
• W2783295481 date "2018-01-22" @default.
• W2783295481 modified "2023-10-15" @default.
• W2783295481 title "Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma" @default.
• W2783295481 cites W1502181242 @default.
• W2783295481 cites W1658971720 @default.
• W2783295481 cites W1982906652 @default.
• W2783295481 cites W1988902102 @default.
• W2783295481 cites W1991365889 @default.
• W2783295481 cites W2019607817 @default.
• W2783295481 cites W2033275491 @default.
• W2783295481 cites W2099752220 @default.
• W2783295481 cites W2101571970 @default.
• W2783295481 cites W2117692326 @default.
• W2783295481 cites W2123105952 @default.
• W2783295481 cites W2123784879 @default.
• W2783295481 cites W2141269240 @default.
• W2783295481 cites W2142443551 @default.
• W2783295481 cites W2143782771 @default.
• W2783295481 cites W2161543112 @default.
• W2783295481 cites W2186593081 @default.
• W2783295481 cites W2222086386 @default.
• W2783295481 cites W2281395530 @default.
• W2783295481 cites W2402433991 @default.
• W2783295481 cites W2542082502 @default.
• W2783295481 cites W2581114680 @default.
• W2783295481 cites W2581283430 @default.
• W2783295481 cites W2589234404 @default.
• W2783295481 cites W2614480329 @default.
• W2783295481 cites W2740254315 @default.
• W2783295481 cites W2758082149 @default.
• W2783295481 cites W2762636298 @default.
• W2783295481 cites W2792333466 @default.
• W2783295481 doi "https://doi.org/10.1186/s40425-018-0315-0" @default.
• W2783295481 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5776777" @default.
• W2783295481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29353553" @default.
• W2783295481 hasPublicationYear "2018" @default.
• W2783295481 type Work @default.
• W2783295481 sameAs 2783295481 @default.
• W2783295481 citedByCount "183" @default.
• W2783295481 countsByYear W27832954812018 @default.
• W2783295481 countsByYear W27832954812019 @default.
• W2783295481 countsByYear W27832954812020 @default.
• W2783295481 countsByYear W27832954812021 @default.
• W2783295481 countsByYear W27832954812022 @default.
• W2783295481 countsByYear W27832954812023 @default.
• W2783295481 crossrefType "journal-article" @default.
• W2783295481 hasAuthorship W2783295481A5000204340 @default.
• W2783295481 hasAuthorship W2783295481A5005321013 @default.
• W2783295481 hasAuthorship W2783295481A5023841393 @default.
• W2783295481 hasAuthorship W2783295481A5034541004 @default.
• W2783295481 hasAuthorship W2783295481A5039044023 @default.
• W2783295481 hasAuthorship W2783295481A5042777250 @default.
• W2783295481 hasAuthorship W2783295481A5045221892 @default.
• W2783295481 hasAuthorship W2783295481A5049425681 @default.
• W2783295481 hasAuthorship W2783295481A5052504518 @default.
• W2783295481 hasAuthorship W2783295481A5053962411 @default.
• W2783295481 hasAuthorship W2783295481A5055738663 @default.
• W2783295481 hasAuthorship W2783295481A5061593455 @default.
• W2783295481 hasAuthorship W2783295481A5066816851 @default.
• W2783295481 hasAuthorship W2783295481A5074756323 @default.
• W2783295481 hasBestOaLocation W27832954811 @default.
• W2783295481 hasConcept C121608353 @default.
• W2783295481 hasConcept C126322002 @default.
• W2783295481 hasConcept C143998085 @default.
• W2783295481 hasConcept C2777472916 @default.
• W2783295481 hasConcept C2777701055 @default.
• W2783295481 hasConcept C2777761686 @default.
• W2783295481 hasConcept C2778963024 @default.
• W2783295481 hasConcept C2780739268 @default.
• W2783295481 hasConcept C2780851360 @default.
• W2783295481 hasConcept C3019894029 @default.
• W2783295481 hasConcept C50382708 @default.
• W2783295481 hasConcept C71924100 @default.
• W2783295481 hasConcept C90924648 @default.
• W2783295481 hasConceptScore W2783295481C121608353 @default.
• W2783295481 hasConceptScore W2783295481C126322002 @default.
• W2783295481 hasConceptScore W2783295481C143998085 @default.
• W2783295481 hasConceptScore W2783295481C2777472916 @default.
• W2783295481 hasConceptScore W2783295481C2777701055 @default.
• W2783295481 hasConceptScore W2783295481C2777761686 @default.
• W2783295481 hasConceptScore W2783295481C2778963024 @default.
• W2783295481 hasConceptScore W2783295481C2780739268 @default.
• W2783295481 hasConceptScore W2783295481C2780851360 @default.
• W2783295481 hasConceptScore W2783295481C3019894029 @default.

• next